Loading stock data…
AbbVie Inc. (ABBV)
$256.46-3.75 (-1.44%)
Market ClosedLast close Sep 4
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AbbVie Inc. in the Healthcare sector is trading at $256.46 with a market capitalization of $451.5B. Wall Street consensus targets $276.59 (29 analysts), implying a +7.8% move over the next 12 months. The stock is currently near its 52-week high of $267.47, remaining 13.6% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $16.99B↑ | $15.00B↓ | $16.62B↑ | $15.78B↑ | $15.42B |
| Gross Profit | $12.70B↑ | $10.78B↓ | $12.07B↑ | $10.47B↓ | $11.08B |
| Operating Income | $6.72B↑ | $4.73B↓ | $5.81B↑ | $4.58B↓ | $5.72B |
| Net Income | $3.61B↑ | $695.00M↓ | $1.82B↑ | $186.00M↓ | $938.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$451.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
72.17
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.66%
ROE
Average efficiency. Growth may require heavy reinvestment.
-106.32%
Volume
Today's trading volume
4.70M
Recent News
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)
Owning these dividend stocks could be a simple way to make money over the long term.
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.